Notice: Essential maintenance to our website is being carried out this weekend 22nd-23rd January so you may experience some disruption in accessing the site.
This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: beta blocker

January 2022 Br J Cardiol 2022;29(1) doi:10.5837/bjc.2022.002

Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy

Kieran F Docherty, John J V McMurray

Abstract

Introduction To date, five pharmacological approaches have been demonstrated to significantly reduce the risk of mortality and prevent hospitalisation for worsening heart failure (HF) in patients with HF with reduced ejection fraction (HFrEF): the combination of a neprilysin inhibitor and an angiotensin-receptor blocker (i.e. sacubitril/valsartan), a beta blocker, a mineralocorticoid-receptor antagonist (MRA) and a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Hereafter, these five agents, which can be prescribed as four pills, will be referred to as the ‘four foundational therapies for HFrEF’.1-11 The combination of these four ther

| Full text

August 2012 Br J Cardiol 2012;19:116

Optimised beta blocker therapy in heart failure A gap between training and provision: a primary-care based ECG survey

Danny Lim, Dev Katarey; Drs Raj Mohindra, Stuart Russell, and Andreas Wolff

Abstract

Optimised beta blocker therapy in heart failure: is there space for additional heart rate control? Dear Sirs, We undertook a similar audit to Russell et al.1 within the heart failure service of a district general hospital auditing the case notes of 96 patients attending over three months. Applying the SHIFT inclusion and exclusion criteria, we identified only seven patients (6.7%) eligible for ivabradine. Using the SHIFT dataset the number needed to treat to prevent a single hospitalisation due to heart failure was 22.2 Extrapolating our data, over 12 months, we would expect to identify approximately 28 suitable patients. Treating 28 patients

| Full text

July 2012 Online First

Beta blockers underused in the elderly with lung disease

Parminder Chaggar

Abstract

There is incontrovertible, large-scale, randomised-controlled evidence for morbidity and mortality benefit of beta-blockers in heart failure (trials include MERIT-HF, COPERNICUS, CIBIS II),1-3 she said, but the evidence for adverse effects in lung disease is based on animal studies, case reports and small scale human studies.4 Beta blockade in COPD, however, is fully endorsed by The European Society of Cardiology (ESC), National Institute for Clinical Excellence (NICE) and Cochrane reviews.5-7 Dr Hardman’s presentation highlighted for trainees an important area where significant improvements can be achieved. Cardiac and respiratory func

| Full text

September 2004 Br J Cardiol 2004;11:408-12

Beta blocker therapy for patients with heart failure in primary care

David Wald, Sarah Milne, Richard Chinn, Margaret Martin, Ranjit More

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now